FindMyKOL

Thomas McPhee, MD

Basic profile

Ophthalmology

ORCIDNone on fileNPIOn fileSign in to see identifiers
✓ Itemized record
RegionScottsdale, AZ · WestSpecialtyOphthalmologyFocusOphthalmology
Active KOLFindMyKOL type: RegionalLatest publication1995Online presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Thomas McPhee is an Ophthalmology physician. OpenAlex indexes 8 publications with 697 citations (h-index 6).

Overview

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
8publications

Publications indexed by OpenAlex. Counts exclude supporting files.

697citations

Citations across these publications.

6h-index

H-index from these publications.

Clinical & industry

trials, payments and federal funding
17companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Industry payments

17 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

  • ABBVIE INC.
    Program year20251 payment
    $30
  • Dompe US, Inc.
    Program year20251 payment
    $29
  • Amgen Inc.
    Program year20251 payment
    $28
All 28 payment records: search, sort and filter.Explore →

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Sensory organs

    93.4%
    Prostaglandin Analog77.4%
    Latanoprost74%Lumigan18%Travoprost8%
    Part D≥162 patients
    Carbonic Anhydrase Inhibitor8.1%
    Dorzolamide Hcl44%Dorzolamide-Timolol40%Simbrinza16%
    Part D<11 patients

    + 1 more class in this area

  • Cardiovascular

    6.6%
    Beta blocker6.6%
    Timolol Maleate100%
    Part D≥18 patients
Where care is delivered (Part B)0% facility · 100% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”